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Lynch Syndrome, also called Hereditary NonPolyposis
Colorectal Cancer (HNPCC), occurs as a consequence
of germline mutations in the mismatch repair (MMR)
system (Stoffel et al., 2009), mainly in MLH1 and MSH2
(>90% of cases), but also in MSH6 and PMS2 [1].
Kastrinos et al., (2011) developed a new web-based
multivariable polytomous logistic regression model for
Providing gene specific Risk Estimates (Model)
(PREMM 1,2,6) that uses genotype-phenotype data from
MLH1, MSH2,a n dMSH6 mutation carriers to generate
individualized predictions for each gene based on perso-
nal and family history characteristics [1] recommends
that a gene prediction of >5% should be a threshold for
a referral for further genetic risk assessment.
A search was performed to obtain a list of patients
seen at the Prince of Wales Hereditary Cancer Clinic
who were sequenced for mutations in MLH1, MSH2 or
MSH6 from 1994 to 2011 with 78% occurring after
2005. A total of 40 patient pedigrees were obtained and
used for the PREMM 1,2,6 model, 29 were mutation
positive and 11 were tested inconclusive. 17% of pro-
bands were selected for testing based on tumour testing
and the remainder were selected based on family history
alone. The model included proband and first and second
degree relative’s age and diagnosis of colorectal cancer
and endometrial cancer. This model also used an inclu-
sion for extra colonic Lynch-associated cancers. Each
proband was also assessed by the Amsterdam II criteria
and given a risk category according to the Australian
Cancer Network Guidelines of average, 1, 2 or 3.
A gene-specific mutation prediction cut off of 5% was
instigative of a mutation for 21 probands (8/12 for
MLH1, missing 33%, 11/13 for MSH2,m i s s i n g2 %a n d
2/4 for MSH6). Based on this limited data, endometrial
cancer was highly predictive for MSH6. The prevalence
of extracolonic, nonendometrial HNPCC-associated can-
cers was higher among MSH2 carriers than MLH1 and
MSH6 carriers, being weakly predictive. The specific
gene estimates were not useful for when tumour analysis
was unavailable, with 59% (17) mutation positive pro-
bands having a low Premm1,2,6 score, which would not
h a v es u p p o r tad e c i s i o nt op u r s u es i n g l eg e n et e s t i n g .
Amsterdam II criteria and Australian Network Guide-
lines have been previously found to be an ineffective
strategy for triage for gene testing for Lynch Syndrome.
Further study on a larger cohort is needed to determine
if the PREMM 1,2,6 model is an effective triage tool for
gene testing for Lynch Syndrome.
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